Cargando…

Update on CSF Biomarkers in Parkinson’s Disease

Progress in developing disease-modifying therapies in Parkinson’s disease (PD) can only be achieved through reliable objective markers that help to identify subjects at risk. This includes an early and accurate diagnosis as well as continuous monitoring of disease progression and therapy response. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Eun Hae, Tennagels, Sabrina, Gold, Ralf, Gerwert, Klaus, Beyer, Léon, Tönges, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869235/ https://www.ncbi.nlm.nih.gov/pubmed/35204829 http://dx.doi.org/10.3390/biom12020329

Ejemplares similares

Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers
por: Tönges, Lars, et al.
Publicado: (2022)

TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis
por: Beyer, Léon, et al.
Publicado: (2020)

Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany
por: Scherbaum, Raphael, et al.
Publicado: (2021)

Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients
por: Richter, Daniel, et al.
Publicado: (2018)

Emerging Immunotherapies for Parkinson Disease
por: Zella, Samis M. A., et al.
Publicado: (2018)

COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany
por: Scherbaum, Raphael, et al.
Publicado: (2022)

SARS-CoV-2, COVID-19 and Parkinson’s Disease—Many Issues Need to Be Clarified—A Critical Review
por: Goerttler, Tsepo, et al.
Publicado: (2022)

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

Propionic Acid and Fasudil as Treatment against Rotenone Toxicity in an In Vitro Model of Parkinson’s Disease
por: Ostendorf, Friederike, et al.
Publicado: (2020)

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
por: Zella, Maria Angela Samis, et al.
Publicado: (2019)

Hospital Admissions for Neurodegenerative Diseases during the First Wave of the COVID-19 Pandemic: A Nationwide Cross-Sectional Study from Germany
por: Scherbaum, Raphael, et al.
Publicado: (2021)

Parkinson’s Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement
por: Hartelt, Elke, et al.
Publicado: (2020)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2019)

Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany
por: Richter, Daniel, et al.
Publicado: (2021)

Data-driven subtyping of Parkinson’s disease: comparison of current methodologies and application to the Bochum PNS cohort
por: Chen, Qiang, et al.
Publicado: (2023)

Increased CSF biomarkers of angiogenesis in Parkinson disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Correlates of polyneuropathy in Parkinson’s disease
por: Kühn, Eva, et al.
Publicado: (2020)

Parkinson’s disease multimodal complex treatment improves gait performance: an exploratory wearable digital device-supported study
por: Scherbaum, Raphael, et al.
Publicado: (2022)

Short-chain fatty acids in the context of Parkinson’s disease
por: Metzdorf, Judith, et al.
Publicado: (2021)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers
por: Stocker, Hannah, et al.
Publicado: (2023)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

A Propagated Skeleton Approach to High Throughput Screening of Neurite Outgrowth for In Vitro Parkinson’s Disease Modelling
por: Schikora, Justus, et al.
Publicado: (2021)

CSF Biomarkers for Alzheimer's Disease Diagnosis
por: Anoop, A., et al.
Publicado: (2010)

Alzheimer’s polygenic risk scores, APOE, Alzheimer’s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years
por: Stocker, Hannah, et al.
Publicado: (2023)

Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein
por: Barkovits, Katalin, et al.
Publicado: (2020)

Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
por: Mankhong, Sakulrat, et al.
Publicado: (2022)

Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study
por: Rohmann, Rachel, et al.
Publicado: (2021)

Letter to the editor: risk comorbidities of COVID-19 in Parkinson’s disease patients in Germany
por: Richter, Daniel, et al.
Publicado: (2020)

Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease
por: Lee, Young-gun, et al.
Publicado: (2022)

Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
por: Zou, Kun, et al.
Publicado: (2020)

Vagal cross-sectional area correlates with parasympathetic dysfunction in Parkinson's disease
por: Huckemann, Sophie, et al.
Publicado: (2023)

Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
por: Richter, Daniel, et al.
Publicado: (2019)

Parkinson Disease Psychosis: Update
por: Friedman, J. H.
Publicado: (2013)

Punding in Parkinson's Disease: An Update
por: Rajalingam, Rajasumi, et al.
Publicado: (2023)

Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
por: Roser, Anna-Elisa, et al.
Publicado: (2017)

Recommendations for Standards of Network Care for Patients with Parkinson’s Disease in Germany
por: Prell, Tino, et al.
Publicado: (2020)

An update on best practice of deep brain stimulation in Parkinson’s disease
por: Hartmann, Christian J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b9gl9nvsmsksa00vko41iaggqa